Loading viewer...
conference
Format: PDF conference
Karyopharm Therapeutics presented clinical and commercial updates on XPOVIO (selinexor) for relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma at the 2020 American Society of Hematology conference. The presentation discusses regulatory strategies, clinical trial designs, and the commercial potential of selinexor alongside other investigational drug candidates.
conference
34 Pages
conference
16 Pages
Immunovia AB
Accelerate Diagnostics 2021 J.P. Morgan Healthcare Conference
conferenceconference
27 Pages
Accelerate Diagnostics, Inc.